Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation

Launched by AZIENDA DI SERVIZI ALLA PERSONA DI PAVIA · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a special dietary supplement made from a plant called Melissa officinalis, which is designed to help improve mood and manage stress. The study will involve healthy adults aged 18 to 65 who are willing to follow the study guidelines. Participants will be randomly placed into two groups: one group will receive the actual supplement, while the other will get a placebo, which looks like the supplement but doesn’t contain the active ingredients. Both groups will take their assigned product daily for three weeks. Researchers will measure changes in mood, stress levels, and a hormone called cortisol, which is linked to stress.

To be eligible for this study, participants must be healthy, meaning they don’t have any serious medical conditions or take medications that might affect mood or stress levels. They also should not have allergies to the ingredients in the supplement or have a history of significant mental health issues. This is a pilot study, which means it’s an early-stage trial aimed at gathering information on how well the supplement works and whether it is safe to use. The study is not yet recruiting participants, but it’s an exciting opportunity for those interested in exploring alternative ways to support emotional well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 65 years
• • Healthy volunteers as assessed by medical history and physical examination
• • Willingness to comply with the study procedures
• Exclusion Criteria:
• • Current use of medications or supplements that may affect mood or cortisol levels
• • Known allergy or sensitivity to Melissa officinalis or phospholipids
• • History of psychiatric disorders (e.g., major depression, anxiety disorders)
• • Significant comorbidities (e.g., cardiovascular, hepatic, renal diseases)
• • Pregnant or breastfeeding women
• • Participation in another clinical trial in the past 30 days